Search

Your search keyword '"Carboplatin/paclitaxel"' showing total 9 results
Start Over Descriptor "Carboplatin/paclitaxel" Journal european journal of cancer
9 results on '"Carboplatin/paclitaxel"'

1. 3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results

Author

Caroline Nickner, Normand Blais, Q. Qin, Peter Ansell, Martin Reck, Vera Gorbunova, Suresh S. Ramalingam, Sergey Orlov, Julien Mazieres, Laszlo Urban, Jiang Qian, Mark D. McKee, M. Jones, J. Dziubinski, E. Juhasz, Fabrice Barlesi, Ulrich Keilholz, Vincent L. Giranda, and E. Kio

Subjects
Oncology, Cancer Research, medicine.medical_specialty, chemistry.chemical_compound, Veliparib, chemistry, business.industry, Internal medicine, Phase (matter), medicine, business, Carboplatin/paclitaxel
Published
2015
Full Text
View/download PDF

2. 2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC)

Author

Jonathan A. Ledermann, Philip Beale, Adrian Cook, Andrés Cervantes, M. Parmar, G. Kristensen, A. Embleton, Eric Pujade-Lauraine, Amit M. Oza, Richard Kaplan, Timothy J. Perren, L. Farrelly, E. Kent, and Jacobus Pfisterer

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, business.industry, Front line, Disease, medicine.disease, Carboplatin/paclitaxel, Internal medicine, Toxicity, medicine, Stage (cooking), Ovarian cancer, business, medicine.drug
Published
2015
Full Text
View/download PDF

3. 3324 NCCTG N0879 (Alliance): A randomized phase II cooperative group trial of carboplatin, paclitaxel, bevacizumab, =/- everolimus (CPB+/-E) for metastatic melanoma

Author

M. Gupta, Svetomir N. Markovic, K. Rumilla, Roxana S. Dronca, J. Allred, Rob Mcwilliams, R. Katipamula, Lisa A. Kottschade, and L. Erickson

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Everolimus, Bevacizumab, Metastatic melanoma, business.industry, Carboplatin/paclitaxel, Internal medicine, medicine, Cooperative group, business, medicine.drug
Published
2015
Full Text
View/download PDF

4. 9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS

Author

Jin-Ji Yang, Yi-Long Wu, Emma Duffield, Y.M. Chen, Masahiro Fukuoka, Y. Rukazenkov, Da Tong Chu, Sumitra Thongprasert, Tony Mok, and Nagahiro Saijo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, biology, business.industry, Carboplatin/paclitaxel, First line treatment, Gefitinib, Egfr mutation, Internal medicine, biology.protein, Medicine, Copy-number variation, Epidermal growth factor receptor, business, medicine.drug
Published
2011
Full Text
View/download PDF

5. 9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)

Author

Celine Pallaud, Martin Reck, Vera Gorbunova, M. Jonnaert, Tony Mok, Chong-Jen Yu, O. Burdaeva, E. Juhasz, B. Szima, and Paul Delmar

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, business.industry, First line, Carboplatin/paclitaxel, Carboplatin/Gemcitabine, Internal medicine, medicine, In patient, Biomarker Analysis, business, Recurrent Non-Squamous Non-Small Cell Lung Cancer, medicine.drug
Published
2011
Full Text
View/download PDF

6. 9120 POSTER Linifanib Plus Carboplatin/Paclitaxel (CP) in Japanese Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) -Phase 1 Preliminary Results

Author

F. Ohvanaqi, Makoto Nishio, X. Li, Isamu Okamoto, Kazuhiko Nakagawa, Noboru Yamamoto, Tomohide Tamura, M. Terashima, T. Horai, and Ikuo Sekine

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, Carboplatin/paclitaxel, Linifanib, chemistry.chemical_compound, chemistry, Internal medicine, medicine, business
Published
2011
Full Text
View/download PDF

7. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial)

Author

S. D. Costa, Werner Meier, A. du Bois, Volker Moebus, W. Schroeder, S. Warms, S. Olbricht, Thomas Bauknecht, Barbara Richter, and H. J. Lueck

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Cisplatin/paclitaxel, business.industry, Internal medicine, medicine, business, Ovarian cancer, medicine.disease, Carboplatin/paclitaxel
Published
2001
Full Text
View/download PDF

8. Treatment of patients with advanced ovarian cancer (FIGO IIb-IV) with cisplatin/paclitaxel or carboplatin/paclitaxel — An interim analysis of the ago study protocol ovar-3

Author

W. Schröder, Werner Meier, S. Olbricht, Jacobus Pfisterer, Volker Möbus, H.-J. Lück, U. Nitz, A. du Bois, and Walther Kuhn

Subjects
Oncology, Cancer Research, Advanced ovarian cancer, medicine.medical_specialty, business.industry, Cisplatin/paclitaxel, Internal medicine, medicine, business, Interim analysis, Carboplatin/paclitaxel
Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results